Novartis’s Zolgensma In Spotlight As Second Death Is Probed

 
• By Kevin Grogan
  
EggTimer
Not much time left before FDA Zolgensma decision • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies